Date | Title | Description | |
---|---|---|---|
23 Feb 2022 | Annual Report regarding remuneration of the members of the Board of Directors | ROVI releases the 2021 annual report regarding remuneration of the members of the Board of Directors | Download |
23 Feb 2022 | Annual Corporate Governance Report | ROVI releases the 2021 Annual Corporate Governance Report | Download |
21 Feb 2022 | Share buy-back , stabilisation and treasury stock programme | Share Buyback Program: transactions conducted between 14 February 2022 and 21 February 2022 | Download |
15 Feb 2022 | On business and financial situation | ROVI has announced that the European Commission has authorised the marketing of Okedi® for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone. | Download |
14 Feb 2022 | Share buy-back , stabilisation and treasury stock programme | Share Buyback Program: transactions conducted between 7 February 2022 and 11 February 2022 | Download |
Pages
Date | Title | Description | |
---|---|---|---|
04 Oct 2018 | Share capital increases and reductions | Private placement capital increase addressed to institutional investors, excluding preferential subscription rights | Download |
02 Oct 2018 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted in the third quarter of 2018 | Download |
24 Sep 2018 | Others on business performance and financial information | Updated information on business, financial position and risk factors | Download |
24 Sep 2018 | Share capital increases and reductions | Intention to raise gross proceeds by means of an offer addressed to institutional investors, excluding preferential subscription rights | Download |
26 Jul 2018 | Información sobre resultados | ROVI releases the 2018 first half results presentation | Download |